Biocryst Pharmaceuticals Inc. (BCRX): A Technical Analysis
BCRX has 36-month beta value of 1.96. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,”
BCRX has 36-month beta value of 1.96. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,”
Company’s 36-month beta value is 1.93.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 2 as “overweight,” 2 as
Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX)’s stock price has plunge by -2.10relation to previous closing price of 4.77. Nevertheless, the company has seen a 1.30% surge
The 36-month beta value for BCRX is at 1.94. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 2
The stock has a 36-month beta value of 1.90. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as
BioCryst Pharmaceuticals, Inc. (BCRX), a biotechnology company, is trading at $11.64 in the current market after plunging 34.90% since the start of the trading session.
© 2024, Powered by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.